Výsledky vyhledávání - "Fifi Nzeza Bambuwu A"

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

Autor: Mesu, V. K. B. K., Kalonji, W. M., Rembry, S., Valverde Mordt, O., Ngolo Tete, D., Prêtre, A., Delhomme, S., Ilunga Wa Kyhi, M., Camara, M., Catusse, J., Schneitter, S., Nusbaumer, M., Mwamba Miaka, E., Mahenzi Mbembo, H., Makaya Mayawula, J., Layba Camara, M., Akwaso Massa, F., Kaninda Badibabi, L., Kasongo Bonama, A., Kavunga Lukula, P., Mutanda Kalonji, S., Mariero Philemon, P., Mokilifi Nganyonyi, R., Embana Mankiara, H., Asuka Akongo Nguba, A., Kobo Muanza, V., Mulenge Nasandhel, E., Fifi Nzeza Bambuwu, A., Scherrer, B., Strub-Wourgaft, N., Tarral, A.

Publikováno v: The Lancet. Infectious diseases.

Summary Background Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the l

Vyhledávací nástroje:

Upřesnit hledání